Though new, Rafarma Pharmaceuticals already holds a unique position in the pharmaceutical industry, representing the most advanced pharmaceutical operations in Russia. The company is focused on the production of generic antibiotics and specialty pharmaceuticals, with the goal of becoming one of the country’s top antibiotic producers over the next 5 years and obtaining a 5% share of the overall Russian pharmaceutical market in just 3 years. Underpinning this strategic goal is the plan to reduce prices on certain key pharmaceutical products by 30%-40%, a move that is expected to help reduce dependence upon western suppliers.
In addition Rafarma plans on developing its own in-house developed and generic pharmaceuticals, as well as identifying potential acquisition targets, including brands, trademarks, and other marketing assets. They also expect to engage in joint products with foreign pharmaceutical companies.
Initially targeted, and applied for, generic medications include the following:
• Anti-cancer drugs (5)
• Anti-microbe and infection drugs (20)
• Heart health drugs (4)
• Anti-ulcer drugs (3)
• Neuroleptics (3)
• Others (2)
Self-developed products include anti-bacterial, anti-viral, anti-infection based products, currently in clinical trials, and patented instruments for medical use (inhaler, injector). The company is working with Christian Albrecht University in Germany to develop drug and related delivery products.
Underlying these developments is the company’s stated social responsibility strategy, corresponding with the government’s goal of achieving complete independence from high-cost imported medications while maintaining top international standards.
For more information, visit www.rafarma.us
Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board